Tailoring solulan C24 based niosomes for transdermal delivery of donepezil: In vitro characterization, evaluation of pH sensitivity, and microneedle-assisted Ex vivo permeation studies

The objective of the study was to formulate olive oil based organogels for the topical application of fluconazole (FLZ), to ensure the efficient delivery of the drug deeper in to the skin layers. Methods: Nine formulations developed by hot-melt method using olive oil, sorbitan monostearate (SMS) and FLZ. Prepared formulations characterized for macro evaluations, pH, spreadibility, viscosity, gel-sol transition, in-vitro diffusion study. Further optimized formulation evaluated for ex-vivo percutaneous permeation, in-vitro antifungal studies and stability studies by similarity index. Results: The results of evaluated parameters ensure the stability and effectiveness of the prepared olive oil based organogels. In-vitro diffusion studied reflects decrease in drug release with increase in surfactant concentration due to increase in viscosity. Moreover, ex-vivo permeation studies revealed that the permeation of FLZ was enhanced for optimized formulations (F6) as compared to the marketed gel formulation. Further, the optimized formulation exhibits the broad zone of inhibition against fungal strains in comparison to control and marketed product during in-vitro antifungal study. Conclusion: The olive oil based organogels formulation shown the enhanced permeation of FLZ from organogel network structure with good antifungal activity as compared to the marketed formulation. Henceforth, the FLZ organogel formulations could be used topically for the effective treatment of fungal infection.

Download Full-text

Nanostructured Lipid Carriers for Intranasal Administration of Olanzapine in the management of Schizophrenia

Current Molecular Pharmacology ◽

10.2174/1874467214666210120160016 ◽

2021 ◽

Vol 14 ◽

Author(s):

Sarbjot Kaur ◽

Ujjwal Nautiyal ◽

Pooja A. Chawla ◽

Viney Chawla

Keyword(s):

Drug Delivery ◽

Ex Vivo ◽

In Vitro Release ◽

Nanostructured Lipid Carriers ◽

Polydispersity Index ◽

Poloxamer 407 ◽

Ex Vivo Permeation ◽

Permeation Studies ◽

Vitro Release

Background: Background: Olanzapine belongs to a new class of dual spectrum antipsychotic agents. It is known to show promise in managing both the positive and negative symptoms of schizophrenia. Drug delivery systems based on nanostructured lipid carriers (NLC) are expected to provide rapid nose-to-brain transport of this drug and improved distribution into and within the brain. Objective: The present study deals with the preparation and evaluation of olanzapine loaded NLC via the intranasal route for schizophrenia. Methods: Olanzapine-NLC were formulated through the solvent injection method using isopropyl alcohol as the solvent, stearic acid as solid lipid, and oleic acid as liquid lipid, chitosan as a coating agent, and Poloxamer 407 as a surfactant. NLC were characterized for particle size, polydispersity index, entrapment efficiency, pH, viscosity, X-ray diffraction studies, in-vitro mucoadhesion study, in- vitro release and ex-vivo permeation studies. The shape and surface morphology of the prepared NLC was determined through transmission electron microscopy. To detect the interaction of the drug with carriers, compatibility studies were also carried out. Results: Average size and polydispersity index of developed formulation S6 was 227.0±6.3 nm and 0.460 respectively. The encapsulation efficiency of formulation S6 was found to be 87.25 %. The pH, viscosity, in-vitro mucoadhesion study, and in- vitro release of optimized olanzapine loaded NLC were recorded as 5.7 ± 0.05, 78 centipoise, 15±2 min, and 91.96 % respectively. In ex-vivo permeation studies, the percent drug permeated after 210 min was found to be 84.03%. Conclusion: These results reveal potential application of novel olanzapine-NLC in intranasal drug delivery system for treatment of schizophrenia.

Download Full-text

Corrigendum to: Transethosomes of Econazole Nitrate for Transdermal Delivery: Development, In-vitro Characterization, and Ex-vivo Assessment

Pharmaceutical Nanotechnology ◽

10.2174/221173850903210813100519 ◽

2021 ◽

Vol 9 (3) ◽

pp. 245-245

Author(s):

Shivani Verma ◽

Puneet Utreja

Keyword(s):

Transdermal Delivery ◽

Ex Vivo ◽

In Vitro Characterization ◽

Research Scholar ◽

Development In Vitro ◽

Econazole Nitrate

The authors wish to add words “Research Scholar” and “Research Supervisor” to their affiliations [1]. The original article can be found online at https://doi.org/10.2174/2211738506666180813122102

Download Full-text

Development of a liquid chromatographic method for the quantification of paromomycin. Application to in vitro release and ex vivo permeation studies

Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy ◽

10.1016/j.saa.2014.06.017 ◽

2014 ◽

Vol 133 ◽

pp. 657-662 ◽

Cited By ~ 3

Author(s):

A. Pujol-Brugués ◽

A.C. Calpena-Campmany ◽

C. Riera-Lizandra ◽

L. Halbaut-Bellowa ◽

B. Clares-Naveros

Keyword(s):

Chromatographic Method ◽

Ex Vivo ◽

In Vitro Release ◽

Ex Vivo Permeation ◽

Liquid Chromatographic Method ◽

Permeation Studies ◽

Liquid Chromatographic ◽

Vitro Release

Download Full-text

FORMULATION, IN VITRO AND EX VIVO CHARACTERIZATION OF MUCOADHESIVE BUCCAL TABLETS FOR ANTIHYPERTENSIVE DRUG

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v11i8.26126 ◽

2018 ◽

Vol 11 (8) ◽

pp. 402 ◽

Cited By ~ 1

Author(s):

Himabindu Peddapalli ◽

Vasudha Bakshi ◽

Narender Boggula

Keyword(s):

Drug Release ◽

Ex Vivo ◽

Surface Ph ◽

Ex Vivo Permeation ◽

First Pass Metabolism ◽

First Pass ◽

Permeation Studies ◽

Buccal Tablets ◽

Pass Metabolism

Objective: Olmesartan belongs to a class of angiotensin II receptor blockers. It is used in the treatment of hypertension. However, it undergoes extensive hepatic first-pass metabolism, resulting in low oral bioavailability is about 26%. The aim of this study was to prepare and evaluate the mucoadhesive buccal tablets of olmesartan with a goal to increase the bioavailability and improve the patient compliance.Methods: Mucoadhesive buccal tablets were prepared by a direct compression technique using mucoadhesive polymers such as hydroxypropyl methylcellulose (HPMC K4M), sodium carboxymethylcellulose (SCMC), and Carbopol 934P. The tablets were evaluated for weight variation, thickness, hardness, friability, surface pH, swelling index, drug content uniformity, in vitro drug release, ex vivo mucoadhesive strength, ex vivo mucoadhesive time, and ex vivo permeation studies. The release kinetics was calculated to determine the drug release mechanism. Results: The physicochemical properties of all the formulations were shown to be within the limits. The optimized buccal tablets F2, F7, and F11 showed satisfactory drug release rates with the diffusion controlled mechanism. Optimized buccal tablets developed for olmesartan possess reasonable mucoadhesive strength, mucoadhesive time, and surface pH was in an acceptable salivary pH 6.76±0.28–6.89±0.34. The ex vivo permeation studies for optimized tablets were shown satisfactory drug permeation and could meet the target flux 0.991 mg h−1cm−2.Conclusion: The obtained results could be used as a platform to develop the buccal delivery of this drug, which bypasses the first-pass metabolism and results in the improvement of bioavailability. Hence, the present study concludes that the olmesartan could be delivered through the buccal route.

Download Full-text